Page 40 - Recursion Pharmaceuticals News Today

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) CEO Christopher Gibson sold 39,690 shares of the business’s stock in a transaction on Thursday, June 2nd. The stock was sold at an average price of $6.09, for a total value of $241,712.10. Following the sale, the chief executive officer now owns 516,268 shares of the company’s stock, […]

Here's why our roundtable likes 10x Genomics, Beam Therapeutics, and Recursion Pharmaceuticals.

Here's why our roundtable likes 10x Genomics, Beam Therapeutics, and Recursion Pharmaceuticals.

Biopharmaceutical company promotes Jennifer Lee to senior vice president of clinical operations, data management and biostatistics SALT LAKE CITY, June ...

Investment Analysts’ price target changes for Tuesday, May 24th: Advance Auto Parts (NYSE:AAP) had its price target reduced by Wells Fargo & Company from $230.00 to $200.00. Wells Fargo & Company currently has an equal weight rating on the stock. Advance Auto Parts (NYSE:AAP) had its price target reduced by Wedbush from $270.00 to $215.00. […]

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Rating) had its price target decreased by analysts at The Goldman Sachs Group from $9.00 to $7.00 in a research report issued to clients and investors on Tuesday, Stock Target Advisor reports. The brokerage presently has a “neutral” rating on the stock. The Goldman Sachs Group’s target price points to […]

Dublin, May 20, 2022 (GLOBE NEWSWIRE) -- The "Global Senolytic Drugs Market, By Type (FOXO4-related peptides, bcl-2 Family Inhibitors, Src Tyrosine...

Digital health market is related to the digital transformation of the healthcare industry, which includes software, hardware, and services. Various...

The global data and analytics market in the pharmaceutical sector was valued at $1.4 billion in 2020...

Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.